Modeling Progressive Fibrosis with Pluripotent Stem Cells Identifies an Anti-fibrotic Small Molecule. by Vijayaraj, Preethi et al.
UCLA
UCLA Previously Published Works
Title
Modeling Progressive Fibrosis with Pluripotent Stem Cells Identifies an Anti-fibrotic Small 
Molecule.
Permalink
https://escholarship.org/uc/item/7h9308sh
Journal
Cell reports, 29(11)
ISSN
2211-1247
Authors
Vijayaraj, Preethi
Minasyan, Aspram
Durra, Abdo
et al.
Publication Date
2019-12-01
DOI
10.1016/j.celrep.2019.11.019
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Modeling Progressive Fibrosis with Pluripotent Stem Cells 
Identifies an Anti-fibrotic Small Molecule
Preethi Vijayaraj1,5, Aspram Minasyan2, Abdo Durra1, Saravanan Karumbayaram4,5,6, 
Mehrsa Mehrabi1, Cody J. Aros1, Sarah D. Ahadome1, David W. Shia1, Katherine Chung1, 
Jenna M. Sandlin1, Kelly F. Darmawan1, Kush V. Bhatt1, Chase C. Manze1, Manash K. Paul1, 
Dan C. Wilkinson10, Weihong Yan8, Amander T. Clark6,9, Tammy M. Rickabaugh1, W. Dean 
Wallace11, Thomas G. Graeber2,3,5, Robert Damoiseaux2,3,5, Brigitte N. Gomperts1,5,6,7,12,*
1UCLA Children’s Discovery and Innovation Institute, Mattel Children’s Hospital UCLA, 
Department of Pediatrics, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
2Department of Molecular & Medical Pharmacology, UCLA, Los Angeles, CA 90095, USA
3California NanoSystems Institute, UCLA, Los Angeles, CA 90095, USA
4Department of Microbiology, Immunology, and Molecular Genetics, UCLA, Los Angeles, CA 
90095, USA
5Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095, USA
6Eli and Edythe Broad Stem Cell Research Center, UCLA, Los Angeles, CA 90095, USA
7UCLA Molecular Biology Institute, UCLA, Los Angeles, CA 90095, USA
8Department of Biology and Biochemistry, UCLA, Los Angeles, CA 90095, USA
9Molecular Cell and Developmental Biology, UCLA, Los Angeles, CA 90095, USA
10Department of Materials Science and Engineering, UCLA, Los Angeles, CA 90095, USA
11Department of Pathology and Laboratory Medicine, UCLA, Los Angeles, CA 90095, USA
12Lead Contact
SUMMARY
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
*Correspondence: bgomperts@mednet.ucla.edu.
AUTHOR CONTRIBUTIONS
P.V. contributed to conception and design, data acquisition, analysis and interpretation, manuscript preparation, and financial support. 
A.M., A.D., S.K., M.M., K.C., D.W.S., and S.D.A. contributed to data acquisition, interpretation, analysis, and manuscript review. 
K.V.B., K.F.D., C.C.M., W.D.W., W.Y., J.M.S., and A.T.C. contributed to data acquisition. M.K.P., C.J.A., D.C.W., T.M.R., and T.G.G. 
contributed to data analysis and manuscript review. R.D. contributed to conception and design, data acquisition, analysis and 
interpretation, and manuscript preparation. B.N.G. contributed to conception and design, data analysis and interpretation, manuscript 
review, final approval of the manuscript, and financial support.
DECLARATION OF INTERESTS
B.N.G. is a co-founder, stock owner, and consultant to InSpira. A patent has been filed on the contents of this manuscript.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.celrep.2019.11.019.
HHS Public Access
Author manuscript
Cell Rep. Author manuscript; available in PMC 2019 December 23.
Published in final edited form as:
Cell Rep. 2019 December 10; 29(11): 3488–3505.e9. doi:10.1016/j.celrep.2019.11.019.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Progressive organ fibrosis accounts for one-third of all deaths worldwide, yet preclinical models 
that mimic the complex, progressive nature of the disease are lacking, and hence, there are no 
curative therapies. Progressive fibrosis across organs shares common cellular and molecular 
pathways involving chronic injury, inflammation, and aberrant repair resulting in deposition of 
extracellular matrix, organ remodeling, and ultimately organ failure. We describe the generation 
and characterization of an in vitro progressive fibrosis model that uses cell types derived from 
induced pluripotent stem cells. Our model produces endogenous activated transforming growth 
factor β (TGF-β) and contains activated fibroblastic aggregates that progressively increase in size 
and stiffness with activation of known fibrotic molecular and cellular changes. We used this model 
as a phenotypic drug discovery platform for modulators of fibrosis. We validated this platform by 
identifying a compound that promotes resolution of fibrosis in in vivo and ex vivo models of 
ocular and lung fibrosis.
In Brief
Vijayaraj et al. describe the generation and characterization of an in vitro progressive fibrosis 
model that is broadly applicable to progressive organ fibrosis. They use it to identify a promising 
anti-fibrotic therapy that acts by activating normal tissue repair.
Graphical Abstract
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INTRODUCTION
Our capacity to heal injured tissue is critically important for survival (Das et al., 2015). 
However, chronic, ongoing injury in any organ with failure to heal can result in tissue 
fibrosis (Martin and Leibovich, 2005). Fibrosis is characterized by overexpression of 
transforming growth factor β (TGF-β) family members and the abnormal and excessive 
buildup of extracellular matrix (ECM) components, such as fibrillar collagen (Nanthakumar 
et al., 2015; Zeisberg and Kalluri, 2013). This accumulation of ECM triggers progressive 
organ remodeling and therefore organ dysfunction. Often, this fibrotic process is driven by 
metabolic and inflammatory diseases that result in organ injury and perpetuate the fibrosis 
(Martin and Leibovich, 2005; Wynn and Ramalingam, 2012). At early stages, the fibrosis is 
thought to be reversible, but upon progression, it can result in end organ failure (Wynn and 
Ramalingam, 2012). The fact that many different diseases all result in the same fibrotic 
response in different organs such as the liver, kidney, lung, and skin speaks for a common 
disease pathogenesis (Rockey et al., 2015; Zeisberg and Kalluri, 2013). Although we 
understand many of the molecular and cellular pathways underlying wound healing and 
fibrosis, we lack relevant human models of progressive fibrosis, mainly due to the challenges 
in reproducing persistent inflammation and cellular plasticity that precedes tissue 
remodeling and fibrosis (Meng et al., 2014; Nanthakumar et al., 2015; Pellicoro et al., 2014; 
Tashiro et al., 2017; Yang et al., 2010). Here, we report an in vitro human model that 
recapitulates the common inflammation-driven progressive fibrosis seen across organs. The 
unique response of induced pluripotent stem cells (iPSCs) differentiated to multiple different 
cell types and cultured on a stiff polyacrylamide hydrogel reproduces the molecular and 
cellular pathways found in progressive fibrotic disorders. This model of progressive fibrosis 
is amenable to drug screening and allowed us to identify a compound with promising anti-
fibrotic potential.
RESULTS
Differentiation of iPSCs to Multiple Cell Types for Disease Modeling
iPSC technology is an attractive tool to model and study complex diseases. Progressive 
fibrosis is one such complex disease that can occur in any organ and arises from the 
cumulative effect of aberrant wound repair involving multiple cell types, including 
fibroblasts, epithelial cells, and immune cells responding to various mechanical and 
chemical stimuli. Our scientific rationale for using iPSCs to model fibrosis in vitro was 
inspired by published studies of other complex diseases, namely Parkinson’s and 
Alzheimer’s diseases, where fibrillary tangles and senile plaques were modeled in a dish 
(Tong et al., 2017). Given the promise of iPSCs for disease modeling and drug discovery and 
the extremely limited therapies available for progressive fibrosis, we undertook the task of 
using iPSCs to model the complex phenotype of progressive fibrosis that could lend itself to 
drug discovery. Every tissue in our body is capable of a wound-healing response that 
involves a scarring phase (Stroncek and Reichert, 2008). Additionally, reprogramming 
human somatic cells to iPSCs from any source and disease state leads to erasure of the 
existing somatic epigenetic memory (Nashun et al., 2015). Hence, we used iPSCs 
reprogrammed from different sources such as dermal and lung fibroblasts and peripheral 
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blood mononuclear cells (PBMCs) and differentiated them into multiple different cell types 
critical for modeling fibrosis (Guzzo et al., 2013; Manuilova et al., 2001; Murray, 2016; 
Passier et al., 2016) (Figures S1A–S1H; Table S1). The differentiated cells were composed 
of over 90% mesenchymal-like cells, as determined by their morphology in cell culture and 
expression of mesenchymal markers such as vimentin (VIM) and SSEA4 (Figures S1C and 
S1D). The mesenchymal-like cells lacked pluripotency markers such as TRA-160 and OCT4 
(Figures S1C and S1E) and showed high expression of the mesenchymal stem cell markers 
CD73, CD90, and CD105 (Figure S1E) We therefore henceforth refer to them as 
mesenchymal-like cells. Importantly, over 30% (60.5% ± 4.3 [mean ± SEM]) of the 
mesenchymal-like cells showed expression of SSEA4 (Figure S1D), a marker associated 
with a fibrosis-initiating cell population in lung (Xia et al., 2014) and oral submucosa (Yu et 
al., 2016). Furthermore, there was a subpopulation of mesenchymal-like cells that expressed 
the epithelial cell marker CD326 (6.7% ± 0.5 [mean ± SEM]) (Figures S1E and S1F). There 
was also a separate small population of cells (4.9% ± 0.64 [mean ± SEM]) that expressed the 
immune cell markers CD45, CD32, CD11b, CD68, or CD14 (Figures S1E, S1G, and S1H). 
Cells with the classic features of macrophages such as heterochromatin, vacuolated 
cytoplasm, microvilli, and whorls of phagocytosed matter were found in low numbers within 
the differentiated cells by transmission electron microscopy (TEM) of the cells in the 
cultures (Figure S1H).
iPSC-Derived Mesenchymal-like Cells Model Progressive Fibrosis
To model progressive fibrosis, we cultured the mesenchymal-like cells on polyacrylamide-
based hydrogels at 13 kPa (Mih et al., 2011), a stiffness that approximates that of a fibrotic 
organ (Clarke et al., 2013; Lagares et al., 2017). Hydrogels were functionalized with 
benzoquinone (Kálmán et al., 1983) and coated with 0.1% gelatin. Our cellular controls for 
this model consisted of primary fibroblasts obtained from the same anatomical sites as the 
site from which the mesenchymal-like cells were derived (parent primary fibroblast) (Figure 
1A). The mesenchymal-like cells and the parent primary fibroblasts expressed SSEA4 and 
CD44 (Figure S1I). However, the mesenchymal-like cells also expressed CD326 and CD45, 
which the parent primary fibroblasts lacked (Figure S1I).
During a 13-day culture period on 13-kPa hydrogels, the mesenchymal-like cells failed to 
form a monolayer like that of the primary fibroblasts cultured under the same condition. 
Instead, the mesenchymal-like cells were highly proliferative and formed a dense, 
progressively enlarging scar-like phenotype (Figures 1A, 1B, S1J, and S1K; Videos S1 and 
S2). While the primary fibroblasts contained fewer proliferating cells (~25%) following 
contact inhibition by day 9 of culture as observed from EdU labeling, the mesenchymal-like 
cells continued to proliferate as scar-like aggregates (Figures 1B and S1L). Consistently, 
these aggregates revealed increased gene expression and protein levels of collagen I, α-
SMA, and TGF-β when compared to the primary fibroblasts cultured under the same 
conditions (Figures 1C and S1M–S1O). Thus, the cultured mesenchymal-like cells with the 
scar-like phenotype in our model share many of the characteristics of the induced fibroblast 
activation (iFA) phenotype that is classically seen in organ fibrosis (Kendall and Feghali-
Bostwick, 2014; Kong et al., 2018; Shinde and Frangogiannis, 2017; Shinde et al., 2017; 
Zeisberg et al., 2000). The iFA phenotype was consistently observed in all mesenchymal-
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like differentiated cell cultures (n = 17 patient samples) (Table S1), while primary fibroblasts 
showed no fibroblast activation phenotype irrespective of the source of tissue from which 
they were isolated.
To understand what was unique about our mesenchymal-like cells, we profiled them further 
and found them to demonstrate plasticity; when cells from our iFA model were negatively 
selected for CD45 expression and sorted for single-positive populations of SSEA4+, 
CD326+, or CD105+ (an auxiliary receptor for the TGF-β receptor complex; Guerrero-Esteo 
et al., 2002) cells and replated onto the 13-kPa hydrogels, each single-positive population 
was able to generate the iFA phenotype within 13 days (Figure 1D). Fluorescence-activated 
cell sorting (FACS) analysis revealed that the single-positive populations were able to 
repopulate into all the other cell types (Figure 1E). The pathological effects of progressive 
fibrosis are associated with cell plasticity, which plays a major role in the phenotypic 
transitions in cell populations that contribute to tissue remodeling in organ fibrosis (Nieto, 
2013; Varga and Greten, 2017). These phenotypic transitions are commonly seen as 
epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions (Fabregat and 
Caballero-Díaz, 2018; Stone et al., 2016). This suggests that in our model, the multipotent 
nature of the mesenchymal-like cells and their plasticity are key in modeling progressive 
fibrosis.
Characterizing the Induced Fibroblast Activation (iFA) Phenotypic Surrogate of 
Progressive Fibrosis
To validate how closely our iPSC-based iFA model recapitulates progressive fibrosis, we 
employed several assays to further characterize the model. First, we used mink lung 
epithelial cells (mLECs) that stably express luciferase under the control of the PAI-I 
(plasminogen activator inhibitor) promoter that is activated in the presence of TGF-β (Abe 
et al., 1994). mLECs were cultured in conditioned media collected from the iFA model at 
different time points (days 2–14). We observed increasing reporter activity over 13 days in 
culture as the iFA phenotype progressed, indicating that the iFA model produced increasing 
amounts of active TGF-β over time (Figures 2A and S2A). Additionally, culture 
supernatants from days 3, 7, and 13 showed increasing amounts of secreted TGF-β1 over 
time as the iFA phenotype progressed (Figure S2B). Consistently, in the iFA model at day 
13, we observed activation of SMAD2/3, which are two major downstream regulators that 
promote TGF-β1-mediated tissue fibrosis (Figure 2B). Parenchymal stiffness increases as 
organ fibrosis progresses (Ben Amar and Bianca, 2016; Clarke et al., 2013; Wells, 2013). We 
used atomic force microscopy (AFM) to measure the local elastic response of the cell 
membranes and the underlying cytoskeleton resulting in stiffness in our iFA model. The 
elastic modulus was calculated by fitting force-indentation curves to the Sneddon contact 
model. The cells in the iFA model exhibited an elastic modulus ranging from 15 to 70 kPa, 
similar to that of fibrotic organs (Clarke et al., 2013; Lagares et al., 2017), and the stiffness 
increased with the progression of the iFA phenotype over time in culture (Figures 2C, S2C, 
and S2D). Senescent cells (20%–30%) were observed with p16INK4A staining in the iFA 
model during progression of the fibrotic phenotype, consistent with what has been described 
in fibrotic lung (Schafer et al., 2017), liver (Lasry and Ben-Neriah, 2015), and kidney tissue 
(Sturmlechner et al., 2017) (Figure 2D). Relative levels of cytokines and chemokines that are 
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normally elevated in patients with fibrotic diseases (Borthwick et al., 2013; Hasegawa and 
Takehara, 2012) showed a similar profile in our disease model using a cytokine array, with 
notable increases in cytokines MCP-1, CXCL12, VEGF-A, interleukin-6 (IL-6), IL-8, and 
CSF3 (Figure 2E). These data suggest that there is a senescence-associated secretory 
phenotype in the iFA model. Using ELISA at different time points in our iFA model, we also 
observed increasing levels of secreted HMGB1 during progression of the phenotype (Figure 
2F). The secretion and cytoplasmic translocation of nuclear HMGB1 can account for the 
secretion of pro-inflammatory cytokines and activation of nuclear factor κB (NF-κB) (Kim 
et al., 2017; Li et al., 2016; López-Novoa and Nieto, 2009; Tadie et al., 2012; Wang et al., 
2017; Zhao et al., 2017) (Figure 2G) The activation of NF-κB in our iFA model is seen by 
its nuclear localization in the cells in our model (Figure 2G). As a damage-associated 
molecular pattern (DAMP) protein, HMGB1 has been reported to be a pro-fibrotic agent in 
liver, renal, and lung fibrosis (Hamada et al., 2008; Li et al., 2014).
We next performed gene set enrichment analysis (GSEA) to integrate the differential gene 
expression from RNA collected at day 4 (pre-iFA phenotype) and day 13 (established iFA 
phenotype) of the iFA model and to identify the top canonical pathways enriched during the 
progression of the iFA phenotype compared to published datasets from human healthy and 
fibrotic lung (idiopathic pulmonary fibrosis [IPF] [GEO: GSE52463]), human healthy and 
fibrotic kidney (chronic kidney disease [GEO: GSE66494]), and human early and advanced 
fibrotic liver (liver steatosis [ArrayExpress: E-MTAB-6863]) tissues (Nakagawa et al., 2015; 
Nance et al., 2014; Ramnath et al., 2018) (Figure 2H). The iFA model showed enrichment of 
genes encoding matrisome, ECM glycoproteins, chemokine-cytokine receptor interaction, 
proteoglycans, secreted factors, and the IL-4 pathway in a pattern similar to that seen in 
fibrotic lung (p = 0.018), kidney (p = 0.033), and liver (p = 0.089) tissues (Figure 2H; Table 
S2). Genes responsible for cell-surface interactions (e.g., integrin 1 pathway) and regulation 
of inflammatory host defenses, cell growth, and differentiation (e.g., cytokine-cytokine 
receptor interactions) were also enriched in the iFA model and across the fibrotic organ 
tissues (e.g., IPF [p < 0.01]) (Figure S2E). On the other hand, healthy human tissues of lung, 
liver, kidney, and pre-iFA phenotype cultures shared similar expression of genes associated 
with normal cell function, including DNA replication and cell cycle pathways (Figure 2H; 
Table S2). Taken together, this characterization of the iFA model revealed that it displays 
many gene expression profiles in common with fibrotic human tissues.
The iFA Model Is More Representative of Human Fibrotic Diseases than Exogenous TGF-β-
Induced Fibrosis Models
To examine how our iFA model compares to the most commonly used fibrosis models in 
drug discovery programs, we performed a head-to-head comparison of our iFA model (that 
has no exogenous addition of TGF-β) to primary hepatic stellate cells (LX-2), primary 
fibroblasts from healthy (LF) and fibrotic lung (IPF_LF), and healthy skin (SF) that were 
exogenously treated with TGF-β for 48 h. The 48–72 h time frame of TGF-β treatment is the 
norm in the field of fibrosis drug discovery, since the cells reach the point of contact 
inhibition by this time. This comparison was first performed using a Human Fibrosis RT2 
Profiler PCR Array to profile the expression of 84 key genes involved in dysregulated tissue 
remodeling during repair and regeneration. Consistent with the known pathogenesis of 
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fibrosis, fibroblast activation (ACTA2) and ECM (COL1A2 and COL3A1) genes were 
upregulated in all models (Figure 3A). Interestingly, TGF-β was upregulated in the iFA 
model but downregulated in the models where TGF-β was given exogenously (Figure 3A). 
Increased fibroblast activation and ECM deposition across the models was also confirmed at 
the protein level by immunoblotting and immunofluorescence staining (Figures 3B, S3A, 
and S3B). However, the iFA model, unlike the other models, showed a strikingly higher 
inflammatory chemokine/cytokine, growth factor, and TGF-β superfamily involved signal 
transduction signature (p < 0.05) (Figure 3A). Next, we examined secreted levels of several 
cytokines/chemokines and the DAMP molecule HMGB1 across all fibrosis models. 
Consistent with what was observed at the gene expression level, we observed significant 
levels of secreted cytokines/chemokines such as IL-6, IL-8, MCP-1, and VEGF-A, and the 
DAMP molecule HMGB1 in our iFA model, whereas the primary fibroblasts that were 
exogenously treated with TGF-β did not show a significant increase in expression of these 
proteins after treatment (Figures 3C and 3D). Additionally, we stained all the models for β-
galactosidase to identify senescent cells. While we saw progressively increasing numbers of 
senescent cells in our iFA model, we did not observe any senescent cells after 48-h treatment 
with TGF-β in the other models (Figure S3C), and these data were consistent with the lack 
of inflammatory signature seen across the TGF-β-induced fibrosis models (Figures 3A and 
3C). This extensive characterization of our model and its comparison with exogenously 
added TGF-β-driven fibrosis models demonstrates a clinically relevant human model that 
phenotypically and functionally resembles inflammation-driven fibroblast activation and 
progressive fibrosis in a dish.
High-Content Phenotypic Screening Identifies an Anti-Fibrotic Small Molecule
Next, given the progressive fibrotic phenotype seen in the iFA model, we developed a 
phenotypic screening assay to identify potential anti-fibrotic drugs. Phenotypic assays are 
ideal when screening for compounds that reverse disease-related cellular phenotypes without 
knowing the precise biological causalities. Moreover, such approaches are more likely to 
yield therapeutically tractable hits than standard enzyme-based assays with better prognosis 
in translation to the clinic. In our case, our primary screen was an iFA-prevention assay 
without a priori knowledge of any targets (Figures 4A and 4B). We identified various 
cellular phenotype parameters that appeared relevant, such as size, fluorescence intensity of 
the iFA phenotype, the shape factor of the cells/aggregates, and the cells’ viability in the 
presence of viability dyes (Calcein AM) (Figure S4A).
The most desired hit compounds would prevent the cells from forming the iFA phenotype 
and instead allow them to grow as a monolayer of viable cells with a spindle-shaped cell 
morphology due to decreased fibroblast activation similar to the morphology of parent 
primary fibroblasts cultured on hydrogels (Figures 1A and S1L). For our initial primary 
screen, we used a simple data-mining strategy that would differentiate the iFA phenotype 
and spindle-shaped cells using area, fluorescence intensity, and morphometric shape analysis 
(Figure S4A).
We exposed our iFA model to compounds from in-house-curated libraries of ~17,000 small 
molecules at a concentration of 10 μM for 7 days. Wells with only DMSO were used as 
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negative controls to assess drug efficacy for preventing the progression of the iFA 
phenotype. To determine assay robustness, we analyzed the iFA phenotype over multiple 
plates and experimental runs. The total fluorescent signal generated per single iFA 
phenotype was found to be proportional to its size. We defined wells that had more than 80% 
viable cells compared to the DMSO-treated controls as not impacted by the toxicity of the 
compounds. Using the standard plate layout in the NIH assay guide, we monitored the signal 
to detect deleterious effects such as drifts or edge effects. All per-well measurements were 
normalized to DMSO control averages. From the primary screen, we identified a compound, 
AA5, that completely prevented the progression of the iFA phenotype (AA5 prevention) 
(Figures 4C–4E). Instead, the cells resembled mesenchymal-like cells and covered the well 
as a monolayer at concentrations ranging from 2 to 150 μM with an IC50 of ~0.9 μM 
(Figures 4F and S4B). There are currently no compounds that have been identified to 
prevent progression of fibrosis. We further refined our primary screen by using a full plate of 
DMSO as solvent control and AA5 as tool compound to assess standard parameters (Z′, SD, 
and coefficient of variance [CV]) for assay performance. We benchmarked our assay by data 
mining for the presence or absence of iFA phenotype and single spindle-shaped cells. We 
were able to achieve a Z′ = 0.55 for the presence/absence of iFA phenotype. We were able 
to further improve our assay performance by deriving a phenotypic index (PI) that is 
calculated as follows: PI = (area covered in the well) × (number of nuclei)/log (number of 
iFA phenotypes detected + 5). Using the PI, we obtained a Z′ = 0.65, which is an excellent 
assay (Figures 4G and 4H). The numerical value of 5 that is added to the iFA phenotype is 
roughly 1 SD of the number of iFA phenotypes found in an average well.
For the iFA phenotype analysis, the signal to basal ratio (S/B) ratio was 59.3-fold, and the 
CVs were 0.31 for the DMSO-treated wells and 3.5 for the AA5-treated wells (Figure 4G). 
For the PI analysis, the S/B ratio was 76-fold, and the CVs were 0.63 for the DMSO-treated 
wells and 0.11 for the AA5-treated wells (Figure 4H). Thus, our assay is suitable for high-
throughput screening.
Our hit rate from the primary screen (chemical and functional genomic screens) was 0.1%, 
which included hits that could partially or completely inhibit the iFA phenotype. For 
example, the JAK/STAT pathway is known to be important in driving fibrosis in many 
organs (Mair et al., 2011; Milara et al., 2018; Mir et al., 2012). Our chemical screen 
identified the JAK2 inhibitor CEP-3379, and our functional genomic screen identified 
knockdown of STAT5b as hits in our primary screen (Figure S4C). The gene expression of 
ACTA2/COL1A1 was consistent with the phenotype observed (Figures S4D and S4E).
Characterizing the Anti-fibrotic Activity of AA5
As AA5 is an unknown small molecule, we decided to characterize its anti-fibrotic effect 
further. We first determined if AA5 had an effect on cellular proliferation. DMSO- and AA5-
treated cells were labeled for 6 h with EdU at different time points during the iFA phenotype 
progression, and we did not detect any significant difference in proliferation rates at 10 μM 
concentration (Figures S4F and S4G). Next, we examined the anti-fibrotic effect of AA5 by 
profiling the expression of several genes involved in tissue remodeling during repair. 
Downregulation of the gene expression of the fibrotic markers α-SMA, collagen I, TIMP-3, 
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and POSTN in response to treatment with AA5 was further confirmed by immunoblotting, 
Luminex, and immunofluorescence analysis (Figures S4H and S4I).
As a secondary screen, we determined whether treatment with AA5 was sufficient to 
promote the resolution of a fibrotic phenotype. 13 days after the generation of the iFA 
phenotype, cells were treated with 10 μM AA5, and within 48 h, AA5 resolved the iFA 
phenotype based on the reduction in levels of collagen I and α-SMA (Figures 5A and S5A–
S5C; Videos S2 and S3). We also examined the outcome of AA5 prevention and AA5 
resolution on cell stiffness and found that AA5 treatment significantly decreased cell 
stiffness (Figure 5B). Additionally, we found that secreted levels of HMGB1 and 
percentages of SSEA4+ cells were attenuated with AA5 treatment (Figures 5C, S5D, and 
S5E).
To determine if AA5 exhibits its preventive and resolutive effects on the iFA phenotype by 
modulating similar cellular mechanisms, we performed transcriptomic analysis of the iFA 
model post-AA5-prevention and AA5-resolution treatments. Using rank-rank 
hypergeometric overlap (RRHO) analysis (Plaisier et al., 2010), we observed a strong 
hypergeometric overlap between the differentially expressed genes upon AA5-prevention 
and AA5-resolution treatments, suggesting overlapping mechanisms by which AA5 prevents 
and resolves the iFA phenotype (Figure S5F). To determine how significantly AA5-treated 
cells correlated to healthy and fibrotic lung, we performed RRHO analysis between the 
differentially expressed genes in healthy and IPF lung datasets compared to datasets of 
differentially expressed AA5-prevention- (Figure S5G) and AA5-resolution-treated (Figure 
S5H) genes. We observed medium to strong hypergeometric overlap between treated (AA5 
prevention or AA5 resolution) and untreated (fibrotic surrogate) iFA cultures as compared to 
the whole lung healthy and IPF tissues, suggesting AA5 treatment drives cells toward a 
healthier lung phenotype. These findings further support the iFA model as a tractable model 
to study progressive fibrosis.
Next, to understand the biological activity modulated by AA5, we performed differential 
gene expression analysis using RNA sequencing (RNA-seq) experiments in the iFA model 
treated with AA5 in both preventative (AA5 prevention) and resolutive (AA5 resolution) 
experiments. We performed functional cluster analysis using the ClueGo tool and observed 
upregulation of Gene Ontology pathways such as response to acute-phase reactants, positive 
regulation of the acute inflammatory response, and regulation of NF-κB import to the 
nucleus. Notably, positive regulation of chemotaxis and activation of acute-phase proteins 
such as IL-6, type I interferon (IFN), and IL-1 were observed after both AA5-resolution and 
AA5-prevention treatments (Figures 5D, 5E, S5I, and S5J).
Because of the inflammatory signature induced by AA5 prevention and AA5 resolution, we 
further examined the acute-phase response in the iFA model treated with and without AA5. 
We observed increased secreted levels of the acute-phase response cytokines IL-6, IL-8, and 
IFN-α with both AA5-prevention and AA5-resolution treatments using Luminex assays 
(Figure 5F). Acute-phase response cytokines play a central role in regulating the innate 
immune response to infection, tissue injury, and DAMPs. Additionally, we observed an 
increase in the acute-phase signaling secondary cytokines MCP-3, VEGF, CSF3, and GRO 
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(Figure 5G). Taken together, AA5 induced an acute-phase response and inhibition of 
HMGB1-mediated chronic cytokine signaling that is associated with scar resolution.
As a consequence of the acute-phase response, pentraxins (PTXs) are released (Bottazzi et 
al., 2010), and scavenging receptors such as CD163L1 on phagocytic cells are activated. 
Scavenger receptors such as CD163L1 play important roles in regulating tissue repair (Doni 
et al., 2015). Our data showed upregulation of modulators of tissue repair, PTX3 and 
CD163L1, within 24 h of treatment with AA5 resolution (Figure 5H). The acute-phase 
signaling seen in the iFA model treated with AA5 prevention and AA5 resolution was 
consistently associated with progressively increasing amounts of PTX3 protein (Figure 5I), 
which also correlated with the iFA prevention and resolution phenotypes (Figures 4 and 5). 
Additionally, we saw attenuation of TGF-β signaling with downregulation of pSMAD2/3 
activity with AA5-prevention and AA5-resolution treatments (Figures 5J and S5K). p-
SMAD2 and p-SMAD3 were differentially regulated in the prevention and resolution 
treatments with AA5, and differential regulation of p-SMAD2 and p-SMAD3 has also been 
reported during a regenerative process (Denis et al., 2016). Taken together, AA5 appears to 
induce an acute-phase response that is associated with scar resolution.
Ex Vivo Anti-fibrotic Efficacy of AA5 in Human LSCs from Patients with Idiopathic 
Pulmonary Fibrosis
As a tertiary screen, we evaluated the efficacy of the hit molecule AA5 using an ex vivo 
model of lung fibrosis (Morin et al., 2013) (Figure 6) and two in vivo models of IPF and 
ocular mucosal fibrosis (Ahadome et al., 2016a, 2016b) (Figure 7). For nearly three decades, 
more than 90% of drug candidates identified to be effective in animal models of fibrosis 
have failed in clinical trials (Raghu, 2017; Spagnolo and Maher, 2017). Therefore, to further 
strengthen our tertiary screen, we examined the efficacy of AA5 in a human ex vivo model 
using fibrotic lung samples. A lung slice culture (LSC) system was established from end-
stage IPF patient lung tissue obtained at the time of lung transplantation. Thin fibrotic lung 
slices were incubated with AA5 (10 μM) or DMSO (1%). The LSCs were viable at 48 h, as 
determined by immunostaining with the proliferation marker PCNA (Figure S6A). 
Following culture, RNA was isolated and quantitative real-time PCR was used to determine 
expression of fibrosis markers. AA5 treatment significantly reduced ACTA-2, COL1A2, and 
TGF-β3 (but not TGF-β1/2) mRNA expression within 48 h relative to DMSO-treated LSCs 
(Figure 6A). Further, we saw decreased levels of secreted TGF-β3 (but not TGF-β1/2), 
TIMP-4, and POSTN protein expression and increased secretion of matrix degrading 
proteases such as MMP-9 and urokinase plasminogen activator (uPA) with AA5 treatment, 
consistent with a tissue repair response (Figures 6B, S6B, and S6C). Additionally, 
immunostaining for HMGB1 revealed exclusively nuclear staining in the AA5-treated LSCs 
compared to the DMSO-treated LSC controls. This was further confirmed by the Luminex 
assay that detected markedly decreased secreted HMGB1 with AA5 treatment (Figures 6C 
and 6D). Additionally, the fibrosis-initiating SSEA4+ cells (Xia et al., 2014) were 
significantly reduced (>50%; p value < 0.001) upon AA5 treatment (Figure 6E).
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AA5 Induces Acute-Phase Response Proteins Promoting Resolution of Fibrosis
To understand the cellular responses modulated by AA5, we performed RNA sequencing on 
LSCs from six different IPF patients treated with AA5 or DMSO. Pathway enrichment 
analysis using ClueGo showed a significant enrichment of acute-phase signaling with nodes 
including neutrophil chemotaxis, IL-1 signaling, and cellular response to DAMPs (Figures 
6F and S6D). Therefore, as with the iFA model, activation of acute-phase response genes 
and fibrosis-resolution genes with AA5 treatment were consistently observed in the LSCs.
Interestingly, unlike AA5 treatment in the iFA model, we did not observe increasing levels 
of secreted protein PTX3 in LSC. Instead, we observed the paralog of PTX3, neuronal 
pentraxin 1 (NPTX1), to be upregulated in the LSCs at the mRNA and protein levels 
(Figures 6G, 6H, and S6E). Scavenger receptors are shed and secreted following phagocytic 
cell activation (Canton et al., 2013). Similar to the AA5-treated iFA cultures, we observed 
the scavenger receptor CD163L1 to be upregulated and secreted in the AA5-treated LSCs 
(Figures 6G and S6E).
These data suggest that AA5 exhibits its anti-fibrotic activity by activating an acute-phase 
response and playing an immune regulatory role. IFNs have immune-regulatory effects and 
are known anti-fibrotic cytokines. To further confirm the activity of AA5, we treated the iFA 
model with recombinant IFN-γ. Cells treated with recombinant IFN-γ showed more 
spreading of cells and less prominent iFA phenotype than the DMSO control, suggesting a 
partial rescue of the iFA phenotype (Figure 6I). Consistent with this, treatment of the LSCs 
with recombinant IFN-γ also revealed a similar expression profile of fibrosis-related 
resolution proteins when treated with AA5 (Figure 6J). This was accompanied by regulation 
of complex fibro-suppressive inflammatory processes such as activation of MMPs and uPA 
and downregulation of TIMPs, elastin, fibronectin, collagens, LOX, and secreted DAMPs. 
Our data suggest that AA5 exhibits its anti-fibrotic effect by activating an acute-phase 
response with cytokines such as IL-6 and IFNs.
AA5 Ameliorates Fibrosis in a Murine Model of Ocular Mucosal Fibrosis
For the in vivo studies, we evaluated the effect of AA5 in both prevention and resolution of 
fibrosis. Mice were sensitized with ovalbumin (OVA) for 14 days and then challenged with 
topical eye drops of OVA for an additional 7 days for the establishment of progressive ocular 
mucosal fibrosis (Figure 7A). During this period, OVA-challenged mice exhibited severe 
eyelid edema, chemosis, conjunctival redness, and tearing compared to naive mice, 
consistent with an inflammation driven fibrotic response (Ahadome et al., 2016b). DMSO 
(1%) or AA5 (0.001–1 mg/1% DMSO) was either applied to the ocular surface on day 14 
together with the OVA challenge for the prevention of fibrosis studies or applied on day 21 
for 7 days following the establishment of fibrosis to determine the efficacy of AA5 in 
resolving fibrosis in a dose-escalation study. The eyes that received 0.1 and 1 mg AA5 
showed less clinical swelling, tearing, and inflammation than DMSO-treated eyes in both the 
preventive and resolutive treatments, and this correlated with the conjunctival histology 
(Figures 7B–7E). The mice were sacrificed at the end of the treatment period, the eyes were 
collected, and the conjunctivae were dissected out for total collagen estimation. Total 
collagen content in the conjunctivae was quantified using a hydroxyproline assay. We 
Vijayaraj et al. Page 11
Cell Rep. Author manuscript; available in PMC 2019 December 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
observed a significant reduction in the collagen content of the conjunctivae after AA5-
prevention and AA5-resolution administration at 0.1- and 1-mg doses that correlated with 
the eye histology (Figures 7C, 7F, and 7G), suggesting that AA5 was able to ameliorate 
OVA-induced fibrosis in a dose-dependent manner.
AA5 Suppresses BLM-Induced Pulmonary Fibrosis in Aged Mice
To define the anti-fibrotic effect of AA5 in a second in vivo model of fibrosis, we used the 
bleomycin (BLM) model of lung injury in aged mice (Figure 7H). 52-week-old mice were 
challenged with BLM (3 U/kg) by the oropharyngeal route to induce lung injury, followed 
by systemic administration of AA5 (20 mg/kg) or DMSO from days 7 to 21 post-BLM 
injury. Naive mice were maintained as controls. The mice were sacrificed on day 21, and the 
total collagen content of the lungs was quantified using the hydroxyproline assay. BLM-
challenged mice had elevated amounts of total collagen compared to their naive controls. In 
contrast, mice treated with AA5 demonstrated significantly reduced total collagen compared 
to the vehicle-treated controls (Figure 7I). The percentage of fibrotic areas from each section 
was quantified using Masson trichrome stain, tiled and imaged on a Zeiss Axioscope 
microscope at 2.5×, and quantified using the spline contour tool using ZEN 2011 software. 
This demonstrated that the vehicle-treated mice displayed significantly more fibrotic areas 
than AA5-treated animals following challenge with BLM (Figures 7J, 7K, and S7A).
DISCUSSION
Four major phases of the fibrogenic response have been described that include initiation of 
the injury, activation of effector cells followed by production of ECM, and then failure to 
resorb the ECM with continued deposition of ECM (Rockey et al., 2015). Our iFA model 
mimics all four fibrotic phases with the secretion of the DAMP molecule HMGB1, the 
activation of fibroblasts to myofibroblasts, the activation of TGF-β, the upregulation of 
inflammatory cytokines and chemokines, and the progressive deposition of collagen, thereby 
creating a phenotypic surrogate for progressive fibrosis.
Fibrotic diseases resulting in organ remodeling and failure are responsible for ~45% of all 
deaths worldwide. Currently, there are very few effective therapies and none that can halt or 
reverse progressive fibrosis (Rockey et al., 2015). Most in vitro models for fibrosis utilize 
the exogenous addition of pro-fibrotic modulators such as TGF-β to their cultures to drive a 
fibrotic response for 48 or 72 h, after which gene and protein expression for markers of 
myofibroblast activation and ECM production are investigated. This approach uses a time 
course that is likely too short to model disease progression and is also subject to modulator-
driven bias. In contrast, our model does not utilize the addition of any external fibrotic 
modulators and is hence unbiased and target-agnostic for progressive fibrosis disease 
modeling and drug discovery. Further, other current in vitro models only seek to inhibit 
fibrosis; that is, unlike our model, these models cannot be used to assess a reversal of 
fibrosis. Importantly, the lack of relevant mouse models for the progressive nature of fibrosis 
is also widely acknowledged (Degryse and Lawson, 2011).
We surmise that iPSCs are uniquely able to generate this phenotype, because they are 
capable of differentiating to multiple different progenitor cell types, and each cell type 
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displays plasticity and can give rise to the other cell types. The pathological effects of 
progressive fibrosis are associated with cell plasticity, which plays a major role in the 
phenotypic transitions in cell populations that contribute to tissue remodeling in organ 
fibrosis (Nieto, 2013; Varga and Greten, 2017). Cellular plasticity is a key feature of fibrosis 
involving bidirectional interactions between epithelial cells and fibroblasts and a dynamic 
interplay between ECM deposition and regression (Rockey et al., 2015). The hierarchical 
relationships among stem cells, lineage-committed progenitors, and differentiated cells 
remain unclear in several tissues due to a high degree of cell plasticity, allowing cells to 
switch between different cell states in both regeneration and pathological conditions. While 
strict lineage hierarchies exist during development and homeostatic tissue turnover, this is 
not the case in pathological conditions such as fibrosis. These phenotypic transitions are 
commonly seen as dedifferentiation (Tetteh et al., 2015) or transdifferentiation (Tata and 
Rajagopal, 2016) and epithelial-to-mesenchymal and mesenchymalto-epithelial transitions 
(Fabregat and Caballero-Díaz, 2018; Stone et al., 2016). Cell plasticity is also apparent from 
single-cell RNA-sequencing studies from fibrotic lung where individual epithelial cells 
express markers of both distal lung and conducting airways, demonstrating that 
undetermined cell types are a characteristic feature of fibrotic tissue (Xu et al., 2016). In 
addition, during acute kidney injury, metabolic constraints have been shown to alter the 
epithelial features of renal proximal tubular cells to undergo a phenotypic switch and 
promote fibrogenesis, leading to chronic kidney disease (Rastaldi et al., 2002; Xu-Dubois et 
al., 2013). Circulating bone-marrow-derived cells can also acquire both and antifibrotic 
phenotypes in liver and kidney and potential other fibrotic organs (Campanholle et al., 2013; 
Trautwein et al., 2015). Single cell RNA-seq analysis is a very powerful tool to define cell 
types using unsupervised clustering based on the whole transcriptome (Pal et al., 2017) and 
may be a useful tool to identify common cellular plasticity signatures at the single-cell level 
across fibrotic organs and our model.
Inflammation has been shown to drive fibrosis. Our studies suggest that altering the 
inflammatory milieu can switch the fibrotic process to a resolutive one, and this is an 
important area for further studies. Inflammatory phagocytic cells are involved in 
inflammation at all stages of the fibrotic process in various organs such as lung, kidney, and 
liver. Following injury, they promote fibrosis by activating NF-κB and secreting profibrotic 
mediators such as TGF-β, which induces fibroblast/myofibroblast activation and ECM 
deposition. However, they also behave as pro-resolutive cells and facilitate resolution of 
fibrosis by producing MMPs and proteolytic enzymes such as uPA and cathepsins that 
degrade fibrotic ECM (Adhyatmika et al., 2015; Karlmark et al., 2010; Reddy et al., 2014; 
Tighe et al., 2011). The pro-resolutive phagocytic cells, such as macrophages, function to 
restore balance in the affected tissue. For example, they function by reducing DAMP 
signaling, increasing apoptotic cell clearance, restoring TIMP/MMP balance, and reducing 
ECM content (Adhyatmika et al., 2015; Galli et al., 2011) in line with the tissue repair 
process. Consistently, in animal models of lung and liver fibrosis, depletion of macrophages 
during the inflammatory phase of fibrosis resulted in a reduction in ECM deposition. In 
contrast, macrophage depletion at the repair phase revealed aggravated ECM deposition 
(Boorsma et al., 2013; Duffield et al., 2005; Gibbons et al., 2011; Song et al., 2000). 
Furthermore, inhibition of NF-κB signaling in the intestine and skin has been shown to 
Vijayaraj et al. Page 13
Cell Rep. Author manuscript; available in PMC 2019 December 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
result in immune homeostasis dysregulation and poor survival outcomes (Wullaert et al., 
2011). Similarly, TNF-α, which is predominantly secreted by macrophages, has been shown 
to promote fibrosis. It is also produced by macrophages during the resolutive phase, and 
mice that are deficient in TNF-α demonstrate delayed resolution of BLM-induced lung 
fibrosis (Redente et al., 2014).
Our data suggest that approaching inflammation-driven fibrosis by targeting endogenous 
agonists of resolution may offer an attractive strategy to treat progressive fibrosis. Targeting 
endogenous agonists of tissue repair for the treatment of IPF is currently being tested in a 
clinical trial with inhaled delivery of IFN-γ for a localized effect, since parenteral delivery 
of IFN-γ did not show any benefit (King et al., 2009).
STAR⋆METHODS
LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by lead contact, Brigitte Gomperts (bgomperts@mednet.ucla.edu). This study did 
not generate new unique reagents.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Induced Pluripotent Stem Cells—University of California iPSC lines were generated 
from IPF lung tissue obtained at the time of lung transplantation and from skin biopsies from 
IPF patients. Both male and female samples were used. Additionally, the following iPSC 
lines from Boston University were used: BU1, BU2, BU3, T1 1Cr NKX2.1, T3 2Cr NKX2.1 
and T4 32Cr NKX2.1. The details are listed in Table S1.
Primary Fibroblasts—Primary fibroblasts were freshly isolated from healthy and IPF 
lung tissue and skin and heart biopsies. Both male and female lines were used. Since the 
cells were largely compared to our iFA model with limited set of samples, no conclusion 
could be drawn on sex as a biological variable.
Human subjects—Deidentified human donor and IPF explanted lung tissue prior to lung 
transplantation were used for reprogramming and ex vivo lung slice culture studies. Patients 
for the generation of IPSCs were randomly chosen and were both male and female. We did 
not find any biological variable with respect to sex in the generation of our model. With 
respect to the ex vivo lung slice culture experiments, as these were efficacy experiments on a 
limited set of samples, no conclusions can be drawn on sex as a biological variable. The 
University of California Los Angeles Institutional Review Board determined that this study 
was exempt from review since the samples were all deidentified and considered waste tissue.
Mice studies—Wild-type C57BL/6 mice aged either 8–10 weeks (ocular mucosal fibrosis 
studies) or 52 weeks (lung fibrosis studies) were purchased from Jackson Laboratories. 
Animals were housed together in groups and maintained in a pathogen-free animal facility in 
a 12-h light-dark cycle in a temperature-controlled room (21.1 ± 1.1°C), with ad libitum 
access to water and food at the Department of Laboratory Animal Medicine at UCLA. All 
procedures were carried out under the UCLA Institutional Animal Care and Use Committee.
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METHOD DETAILS
Generation of Induced Pluripotent Stem Cells—For the generation of iPSCs, skin 
and lung biopsies and PBMCs were procured with appropriate patient consent and institute 
IRB approval. The iPSCs were generated according to established protocols (Karumbayaram 
et al., 2012). Briefly, the punch biopsy samples were chopped and incubated in 2% animal 
origin free collagenase solution for 90 min at 37°C. The dissociated cells were plated in 
MSCGM-CD (Lonza) medium to generate primary fibroblasts. For the generation of iPSC’s, 
1 × 105 primary fibroblasts were transduced with STEMCAA (kind gift from Dr. Darrell 
Kotton, Boston University, MA) vector concentrate (7 × 106 TU/ml) in MSCGM-CD 
medium. Five days post-infection, cells were re-plated in 50:50 TeSR2/Nutristem containing 
10 ng/ml bFGF until iPSC-like colonies appeared. The colonies were picked mechanically 
and cultured in CELLstart-coated dishes. Three independent iPSC lines per tissue sample 
were generated.
Differentiation of iPSC into mesenchymal-like cells to model progressive 
fibrosis—Differentiation of iPSC for modeling progressive fibrosis was generated 
according to published protocols (Wilkinson et al., 2017). Briefly, iPSCs were dissociated 
using 1 mg/ml of dispase, rinsed twice and then cultured in non-adherent dishes in 
DMEM/F12 medium supplemented with 10% FBS, 1x Glutamax, 10nM Non-essential 
amino acids and 0.1mM monothioglycerol (MTG) for the generation of embryoid bodies. 
After 4 days, the embryoid bodies were collected gently and plated on gelatinized dishes to 
allow to adhere and cultured in media containing DMEM/F12 medium supplemented with 
10% FBS, 1x Glutamax and 10nM non-essential amino acids and allowed to differentiate for 
an additional two weeks. The outgrowths from the embryoid bodies were collected by 
trypsinization and passaged for expansion and cryopreservation.
Generation of an Induced Fibroblast Activation (iFA) Phenotypic Surrogate of 
Progressive Fibrosis—Mesenchymal-like cells were cultured on 13 kPa functionalized 
polyacrylamide gels that were prepared as follows. 187.5 μL of 40% acrylamide, 60 μL of 
2% bis-acrylamide and 8.55 μL of sodium bisulfate in a final volume of 990 μL of water was 
incubated for 20 min at room temperature to degas the mixture. To this mixture, 0.10% 
ammonium persulfate and 0.15% TEMED were added, mixed and 100 μL of the solution 
was added onto a 0.4% 3-(Trimethoxysily) propyl methacrylate pH 3.5 treated coverslip. A 
2% dimethyldichlorosilane in chloroform treated round glass coverslip was then inverted on 
the acrylamide solution and allowed to polymerize for 15 min between the two surfaces. The 
top coverslip was gently removed, and the bottom coverslips with the hydrogel were 
transferred to appropriate multi-well low adherent tissue culture plate containing coupling 
buffer (0.1 M sodium phosphate dibasic, 0.1 M sodium phosphate monobasic) pH8. To 
functionalize the hydrogel, 1 part of 0.1 M p-benzoquinone in dioxane was added to the 
hydrogels containing 4 parts of coupling buffer and incubated at 37°C for 30 min. The gel 
was then successively washed with 20% dioxane in water, water, 0.1 M sodium acetate 
buffer at pH 4.0 containing 1.0 M sodium chloride, 0.1 M sodium bicarbonate solution at pH 
8.5 containing 1.0 M sodium chloride, and finally with coupling buffer at pH 7.5. The 
hydrogels were then coated with 0.1% gelatin for 2 hr prior to seeding the cells. Cells were 
seeded at a density of 3000 cells/cm2.
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Activated PAI-1 Activity—Quantitation of biologically active TGF-β levels was 
performed using mink lung epithelial cells stably transfected with plasminogen activator 
inhibitor-1 promoter/luciferase construct, in which luciferase activity represents bioactive 
TGF-β levels according to established protocols (Mazzieri et al., 2000). Briefly, cells in the 
iFA model were serum starved for 30 hr and conditioned media was collected at different 
time points. 2.5×104 mink lung epithelial cells were seeded per well in a 96-well plate and 
allowed to adhere to the plate for 3 hr. The medium was then replaced with conditioned 
media from the iFA model. Separately, control medium containing increasing concentrations 
(10ng/ml – 30 pg/ml range) of rTGF-β1 was used to generate a standard curve. After 24 hr 
of incubation at 37°C, cells were lysed with equal quantity of Bright-Glo Luciferase Assay 
System (Promega) and luminescence was measured using a DTX 880 multimode detector. 
The luciferase activity that was recorded as relative light units (RLU) was interpolated to 
TGF-β1 activity (pg/mL) using the TGF-β standard curve.
Assessing Proliferation by EdU Labeling—Cells were incubated with 10μM EdU 
(Invitrogen) at specified time points of culture for 6 hr, fixed with 4% PFA, and detected by 
staining with Alexa594-azide according to the manufacturer’s instructions. The cells were 
additionally counterstained with Vimentin and/or α-SMA and DAPI.
Decellularization of Primary Fibroblasts and iFA Model—Coverslips were gently 
washed with PBS and subjected to repetitive 30-minute freeze-thaw cycles in water, six 
times in total. The water was then replaced with 25 mM ammonium hydroxide containing 
0.5% Triton X-100 and incubated at room temperature for 15 minutes. The coverslip was 
then washed twice with PBS and fixed with 4% PFA for 10 minutes and processed for 
immunostaining.
Multiplex Analysis of Cytokines—The Milliplex human cytokine/chemokine Panel IV, 
human TIMP Panel 2, and human TGFβ 1,2,3 magnetic bead kits (EMD Millipore) were 
used per manufacturer’s instructions. Prior to plating, all samples tested for human TGFβ 
only were activated and neutralized with 1.0 N HCl and 1.0 N NaOH, respectively. Briefly, 
25 μL of undiluted or treated cell culture supernatant samples were mixed with 25 μL of 
magnetic beads and allowed to incubate overnight at 4°C while shaking. After washing the 
plates with wash buffer in a Biotek EL×405 washer, 25 μL of biotinylated detection antibody 
was added and incubated for 1 hour at room temperature while shaking. 25 μL of 
streptavidin-phycoerythrin conjugate was then added to the reaction mixture and incubated 
for another 30 minutes at room temperature while shaking. Following additional washes, 
beads were resuspended in sheath fluid, and fluorescence was quantified using a Luminex 
200 instrument. Similarly, a custom magnetic Luminex assay kit of select analytes (R&D 
Systems) was used per manufacturer’s instructions. Cell culture supernatants were prepared 
with a 2-fold dilution. 50 μL of diluted sample were added to 50 μL of provided micro-
particle cocktail and incubated for 2 hours at room temperature while shaking. After 
washing with wash buffer, 50 μL of biotin antibody cocktail was added and incubated for 1 
hour at room temperature while shaking. Following additional washes, 50 μL of diluted 
Streptavidin-PE was then added for incubation for 30 minutes at room temperature while 
shaking. The plate was then washed again and the micro-particles resuspended in 100 μL 
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wash buffer. After an additional 2-minute incubation while shaking, the data was acquired 
using a Luminex 200 instrument. For all multiplex assays, data was analyzed using 
MILLIPLEX Analyst 5.1 software. Kits used were TGFβ 1,2,3 (MILLIPORE: 
TGFBMAG-64K-03), TIMP Panel 2 (MILLIPORE: HTMP2MAG-54K), Cytokine/
Chemokine Panel IV (MILLIPORE: HCY4MG-64K-PX21); Custom Luminex (R&D: 
CUST01704 13). Multiplexing LASER Bead Technology service from Eve Technologies 
Corp (Calgary, Canada) was used to simultaneous analyze several cytokines, chemokines 
and growth factors in a single assay from the iFA model at specified time points using the 
Human Cytokine Array / Chemokine Array 64-Plex Discovery Assay based on a 
MILLIPLEX® MAP assay kit from Millipore according to their protocol. The assay 
sensitivities of these markers range from 0.1 – 55.8 pg/ml.
Quantification of Secreted HMGB1 and NPTX1—Conditioned media at different time 
points of progression of the phenotype, and on prevention and resolution drug treatments 
were collected and quantification of protein was performed using the IBL man HMGB1 
ELISA kit or LSBio NPTX1 ELISA kits per manufacturer’s instructions. 10 μL of each 
supernatant sample was added to anti-HMGB1 polyclonal antibody-coated plate and 
incubated for 20 hours at 37°C. All liquid was then removed, and the plate manually washed 
5 times with wash buffer. 100 μL of enzyme conjugate was then added and incubated for 2 
hours at room temperature. After washing again, color solution was added at 100 μL per 
well and incubated for 30 minutes at room temperature. Following an additional five washes, 
the plate was incubated with 90 μL of TMB substrate for another 15 minutes at 37°C in the 
dark. The reaction was then stopped by addition 100 μL of stop solution. Absorbance was 
measured at 450nm using a SpectraMAX Plate Reader. Data was analyzed using SoftMax 
Pro software.
In Situ Cell Elasticity Measurements Using Atomic Force Microscopy (AFM)—
Tapping mode AFM using the Bruker BioScope Catalyst Atomic Force coupled with Zeiss 
LSM5 Confocal Fluorescence Microscope was used on the cells at 37°C in cell culture 
media. AFM deflection images of cells were used in the imaging experiment. In the force 
measurement, sharp silicon nitride AFM probes (tip radius, 20 nm) were employed (Bruker 
Corp., USA). The spring constants of AFM tips were calibrated to be 0.10–0.11 N m−1 and 
deflection sensitivities were 45–50 nm V−1, using Thermo K Calibration (Agilent 
Technologies, USA). The approaching/retracting speed of the AFM tip during the force 
curve measurement was 6 μm s−1. Force–distance curves were recorded to obtain cell 
elasticity (Young’s modulus, E) of individual cells. For each time point, at least 20 single 
cells, 20 cells at the base of the iFA and 20 cells at the tip of the scar were measured with 
over 15 force–distance curves per cell to obtain significant results. The Young’s modulus 
was calculated via the Scanning Probe Image Processor (SPIP) software (Image Metrology, 
Denmark) by converting the force–distance curves to force–separation curves and fitting the 
Sneddon variation of the Hertz model, which describes conical tips indenting elastic 
samples.
Fibrosis Models with the exogenous addition of TGF-β—Hepatic Stellate Cell 
(LX-2) was purchased from Millipore. Primary skin, healthy lung and IPF lung fibroblasts 
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were prepared from punch biopsies collected from patient samples according to the 
Institution’s IRB approvals. Three patient lines were used for each experiment. 100,000 cells 
were seeded in a 35mm dish and allowed to grow to confluency of 48 hours. After a 24-hour 
serum starvation, the media was replaced with serum-free media containing either 2ng/ml 
rhTGF-β for the LX-2 cell line or 10ng/ml rhTGF-β for all other primary cultures. Untreated 
cultures in serum free were maintained as controls. After 48 hours with daily media changes, 
samples were collected for either RNA or protein analysis.
Phenotypic High-Content Drug Screen—A phenotypic high-content drug screen was 
established to identify compounds capable of preventing the iFA phenotype in a 96-well 
format. Toward this end we utilized an ImageXpress XL high-throughput imager with a 4x 
Plan objective (N/A 0.20) and image based focusing. Briefly, 100 μL media were plated in 
each well of 96 well plate using a Thermo Multidrop non-contact dispenser. Using a custom 
V&P pin tool mounted to a Beckman FX liquid handler, 1.5μL compounds or DMSO were 
added. Mesenchymal-like cells were added as a suspension using the Multidrop at a density 
of 3.5×103 cells/well. The resulting compound concentration was 10 μM. Cells were imaged 
after 7 days of incubation at 37°C and 5% CO2: A final of 0.5 μg/ml of Calcein AM and/or 
10 μg/ml propidium iodide (viability dye) with 1 μg/ml Hoechst 33342 were added and 
imaged using the ImageXpress XL system. Data mining was performed using a custom 
module consisting of the following steps: The image background was removed using a top-
hat filter with 25 μm round shape polisher. Next, we identified areas with iFA phenotype and 
individual spindle-shaped cells: iFA phenotypes were defined by size with a cut-off of 60 to 
200 micron and an intensity of at least 200 gray scales over background. Individual spindle-
shaped cells were identified as smaller objects with cut-offs from 15 to 100 micron and a 
lower intensity of at least 70 gray scales over background.
We also performed additional morphometric measurements by counting labeled cell nuclei 
and measuring total area covered with cells per well. The data resulting from the screen were 
batch exported through MetaXpress and uploaded into our Collaborative Drug Discovery 
(CDD) cloud based database (Ekins and Bunin, 2013). Hits were selected on a cut-off of 
more than 3 standard deviations from mean using data normalized to reference wells in each 
plate. IC50 values (the half maximal inhibitory concentration) from confirmation 
experiments were calculated from dose-response signal curves using the Prism software 
(GraphPad Software). Signal-to-background (S/B) ratio, standard variation and variation 
coefficients were calculated as the signal of DMSO treated wells divided by the signal of the 
hit compound (AA5) treated wells. We used Z’ values to measure assay quality which was 
calculated by the formula of Z’ = 1–3(SDTotal+SDBackground)/(MeanTotal–
MeanBackground) (Inglese et al., 2006) where SDTotal and Mean-Total are the standard 
deviation and mean of signal for DMSO treated wells, and SDBackground and 
MeanBackground are the standard deviation and mean of signal for AA5 treated wells. Data 
normalization and curve fitting were performed as previously reported (Kariv et al., 1999). 
We obtained Z’ values for the number of iFA phenotypes and also calculated a phenotypic 
cell index as the product of cell number × area / Log(number of iFA phenotypes +5). The 
assay was standardized using 50% of the plate with 0% DMSO and 50% of the plate with 
1% DMSO. This was done is triplicate per day and repeated on three different dates in order 
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to determine DMSO toxicity and assay reproducibility with minimum-to-none inter-plate 
and intra-plate variability. Reproducibility was determined by averaging the number of foci 
in all the wells per plate and comparing to other plates run on the same day and different 
dates. Toxicity was determined as wells showing < 80% viability compared to the 0% 
DMSO wells. The assay was then run using the Prestwick chemical library and the LOPAC 
library (2560 compounds) in duplicate on two separate days in order to standardize the assay 
performance. Due to the lack of a tool compound, a positive control could not be used. For 
the primary screen, ~17,000 compounds were screened in singlets. Secondary screening 
using α-SMA and collagen deposition was employed to further ensure efficacy and 
resolution of the iFA phenotype of the compounds. For the resolution screen, cells were 
seeded in a 96-well plate as mentioned above and compounds were added at day 13 to 
analyze their capacity to resolve the iFA phenotype using the same readouts as above. Dose 
response experiments were carried out as in the secondary screen but with at least 12 steps 
of a 1:1 dilution resulting in final compound concentrations from 500 μM to high nanomolar 
ranges.
For the functional genomic screen, a pilot of 500 clones were custom-picked from our in-
house arrayed shRNA libraries targeting about 100 genes with an emphasis in coverage of 
desirable target classes such as kinases, proteases, phosphatases, GPCRs and ion channels. 
Oligonucleotides encoding each shRNA were cloned into linear pLX304 and entry vectors 
by 5min room temperature ligations, transformation of TOP10 cells, and selection on LB/
blasticidin broth according to the vector manuals (Transomics Technologies). To transfer 
RNAi cassettes to the desired destination vectors, one-hour LR Clonase reactions 
(Invitrogen) were performed, transformed into TOP10 cells, and selected with 10mg/ml 
Blasticidin. Clones were verified by restriction digest due to the high fidelity of the Gateway 
(Invitrogen) recombination reactions. Lentiviral particles were produced according to 
manufacturer’s instructions (Invitrogen). Functional titer was determined using the 
mesenchymal-like cell line to ensure optimal transduction using the formula (Number of 
colonies) × (Dilution factor)/0.01. Transductions were carried out in a final volume of 100 
μL medium in 96-well plates seeded with 10,000cells/cm2 per well on day 2 of seeding. The 
following day, medium was replaced with complete medium supplemented with 10mg/ml 
Blasticidin. Resistant clones were grown out and cultured on 12kPa hydrogels in order to 
determine presence/absence of iFA phenotype.
RNA Preparation and Expression Analysis—In-vitro cultures of PF and cells in the 
iFA model were washed once with PBS and total RNA from the samples were extracted 
using the RNeasy Mini Kit (QIAGEN) according to the manufacturer’s instructions. For the 
lung slice cultures (LSC), tissues were snap-frozen after treatment and stored at −80°C until 
RNA isolation. Lung slices were homogenized using a handheld homogenizer and passing 
the homogenate through a Qiashredder (QIAGEN). Total RNA from the LSC and cells from 
the disease model were extracted using the RNeasy Mini Kit (QIAGEN) according to the 
manufacturer’s instructions. The RNA concentrations were measured on a NanoDrop 
ND-1000 spectrophotometer. Single-stranded cDNA was synthesized from 200ng of total 
RNA using Superscript IV and random hexamer primers (Invitrogen) in a volume of 20 μl. 
cDNA was then used for qRT-PCR analysis. PCR reactions were performed using Taqman 
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Gene Expression Assay mix (Applied Biosystems) according to the manufacturer’s 
instructions. qRT-PCR reactions were performed using the StepOnePlus (Applied 
Biosystems). Relative gene expression was calculated using the 2−ΔΔCt method, with 18S 
Cat. # 4331182 (Invitrogen) as housekeeping gene. For the RT2qPCR arrays, cDNA from 
DMSO and AA5 treated iFA and was added to the RT2 qPCR iTaq Universal SYBR green 
Master Mix (Biorad). 20 μL of the experimental cocktail was added to each well of the 
Fibrosis PCR (QIAGEN). Real-Time PCR was performed on the StepOnePlus qPCR system 
(Applied Biosystems) using SYBR green detection according to the manufacturer’s 
recommendations. All data from the PCR was collected and analyzed by SA Bioscience’s 
PCR Array Data Analysis Web Portal.
RNA Sequencing Analysis of Stepwise Progression, iFA (AA5) and LSC—
Libraries for RNA-Seq were prepared with the Nugen human FFPE Kit (LSC). The 
workflow consisted of cDNA generation, end repair to generate blunt ends, adaptor ligation, 
adaptor cleavage and PCR amplification. Different adaptors were used for multiplexing 
samples in one lane. Sequencing was performed on the Illumina Nextseq500 with a single 
read 75 run.
iFA phenotypes from the mesenchymal-like cells (iFA model, day4 and day13), IPF whole 
lung tissue from the previously published data (Koyama et al., 2013) and iFA model post-
AA5-prevention and AA5-resolution treatment were analyzed using the following method. 
The reads were aligned to the NCBI build 37.2 transcript set using Bowtie2 version 2.1.0 
and TopHat version 2.0.9. TopHat’s read alignments were assembled by Cufflinks version 
2.2.1. Technical replicates were combined and aligned together in all cases except for the 
AA5-treated model. The gene expression estimates were then log2-transformed and genes 
with no reads across all samples were removed from further analysis.
LSC from IPF patients treated with AA5 or DMSO for 48 hours were analyzed using the 
following method. Data quality check was done on Illumina SAV. Demultiplexing was 
performed with Illumina Bcl2fastq2 v 2.17 program. The reads were first mapped to the 
latest UCSC transcript set using Bowtie2 version 2.1.0 and the gene expression level was 
estimated using RSEM v1.2.15. TMM (trimmed mean of M-values) was used to normalize 
the gene expression. The gene expression estimates were then log2-transformed and genes 
with no reads across all samples were removed from further analysis.
Gene Set Enrichment Analysis (GSEA)—Canonical pathways GSEA (Mazzieri et al., 
2000) was performed using 1,006 canonical pathways (CP) defined by the Broad Institute’s 
Molecular Signatures Database (MSigDB). Gene sets with less than 10 genes were excluded 
from the analysis. Published datasets from fibrotic organs were used for the comparisons to 
the iFA model. For calculating the normalized enrichment scores (NES), genes were ranked 
based on the signal-to-noise ratio. After enrichment results from the whole lung, liver and 
kidney tissue and iFA model were obtained, gene sets were ordered based on the average 
NES rank between the pairwise analyses.
The Rank Rank Hypergeometric Overlap (RRHO) Analysis—The rank rank 
hypergeometric overlap (RRHO) (Plaisier et al., 2010) was calculated using the web 
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application (https://systems.crump.ucla.edu/rankrank/rankranksimple.php). The step size of 
1 was used to bin the ranked items to improve the run time of calculating the hypergeometric 
distribution. Genes were ranked based on their differential expression in comparison groups 
using a log10-transformed t test P value with the sign denoting the direction of change.
Functional Network Analysis—The gene list of interest in each analysis was compiled 
by pairwise generating log2-transformed gene expression fold changes between AA5-treated 
and untreated cases. Only log2-transformed fold changes greater than −1.3 and less than 1.3 
were considered significant for further analysis. From the resulting matrix, a co-expression 
correlation matrix was calculated, and genes were ranked based on how often they had 
correlation greater than 0.7. For AA5-prevention-treated (AA5-resolution-treated) iFA 
model 54 (82) genes upregulated and 58 (75) genes downregulated after AA5 treatment were 
included in the network analysis. For AA5 treated lung slice cultures 68 genes upregulated 
and 57 genes downregulated after AA5 treatment were included in the network analysis.
A Cytoscape plug-in ClueGo (Bindea et al., 2009) was used to visualize functionally 
grouped terms that contained genes from the list of interest in the form of network. The 
terms in Biological Processes, Cellular Component, Immune System Process and Molecular 
Function Gene Ontologies from February 2017 version were analyzed. Terms sharing genes 
were linked together into functional groups based on kappa score level ≥ 0.4. Only terms 
with two-sided hypergeometric p value ≤ 0.05 were kept.
In Vivo Efficacy of AA5 using murine model of ocular mucosal fibrosis—
Female C56/Bl7 mice 8–10 week of age were used for all the experiments. The mice were 
housed in the institute’s vivarium in compliance with the Animal Research Committee. 
Immune-mediated conjunctivitis was induced by i.p. injection of 200 μL of immunization 
mix containing: 10 μg Ovalbumin (OVA) (Sigma-Aldrich), 4 mg aluminum hydroxide 
(Thermo Scientific), and 300 ng of pertussis toxin (Sigma-Aldrich). After 2 weeks, mice 
received topical OVA challenge (250 mg) once a day for 7 days for the development of 
fibrosis. To evaluate the efficacy of AA5 in preventing fibrosis, topical OVA challenge was 
accompanied by addition of 1, 10, 100 or 1000 μg/mouse (n = 12) AA5 administered in both 
eyes in a volume of 5 ul for a total of 7 days. To evaluate the efficacy of AA5 in resolving 
fibrosis, topical OVA challenge was continued for an additional 7 days (days 14–21) after 
the initial OVA sensitization for the development of fibrosis. From day 21 to 28, OVA 
challenge was accompanied by addition of 1, 10, 100 or 1000 μg/mouse (n = 12) AA5. 1% 
DMSO administered in both eyes in a 5 μL volume of PBS was used as control. Both eyes 
were scored in the same manner. For the scoring, a cumulative score of eyelid swelling (out 
of 3) and tearing (out of 3) was taken. At the end of the experiment at day 21 (prevention 
studies) or day 28 (resolution studies), mice were sacrificed and whole eyes were collected, 
fixed in 10% (v/v) formalin and processed by the standard methods for paraffin embedding. 
Sections (5 μm) were stained with Gomori Trichrome or H&E and imaged. Tissue sections 
were reviewed by 4 independent observers, including two observers who were blinded to the 
groups - a pathologist and another researcher. Conjunctivae were dissected from whole eyes 
and either processed for RNA or hydroxyproline assay.
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In Vivo Efficacy of AA5 using murine model of pulmonary fibrosis—C56/Bl7 
male mice 52 week of age were used for all the experiments. The mice were housed in the 
institute’s vivarium in compliance with the Animal Research Committee. Animals were 
lightly anesthetized with 2% isoflurane and BLM hydrochloride (3U/kg) in 50 μl of saline 
(0.9%) was administered via oropharyngeal aspiration using a micropipette (De Vooght et 
al., 2009; Stout-Delgado et al., 2016). 20mg/kg of AA5 or DMSO suspended in vehicle 
containing carboxymethylcellulose sodium (0.5% w/v), NaCl (1.8% w/v), Tween 80 (0.4% 
w/v), benzyl alcohol (0.9% w/v) was administered intraperitoneally from days 7–21 post 
BLM injury. Mice were sacrificed on days 21 for collection of tissue for hydroxyproline 
quantification and histology.
Ex vivo Efficacy of AA5 using Fibrotic Lung Slice Culture System—All human 
samples were obtained in accordance with institute IRB. Tissue for lung slice experiments 
was obtained from patients with Idiopathic Pulmonary Fibrosis (IPF) at the time of lung 
transplant. IPF lungs were cored using an 8 mm diameter core, and manually sliced to 
produce relatively identical slices. Lung slices were cultured for 48 hr in DMEM/F12 
supplemented with 10% FCS in a rocker culture system at 37°C and 5% CO2 in the presence 
of 1% DMSO (control) or 10 μM AA5 (efficacy treatment). 24 LSC samples were prepared 
for each treatment per patient sample. Media was collected every 24 hr for luminex assays 
and replaced with fresh control and treatment medium for the specified incubation time. 
Samples were collected for both RNA isolation and paraffin embedding at 48 hr.
Immunofluorescence—Cells grown on coverslips were fixed in 4% paraformaldehyde 
(PFA) for 10 min at room temperature, washed thrice with TBS buffer supplemented with 
0.1% Tween 20 (TBST). Lung samples were fixed overnight in 4% PFA at room 
temperature, washed 3 times in PBS, dehydrated and then infiltrated and embedded with 
wax. Five-micron sections were collected on glass slides, deparaffinized and rehydrated. 
Heat-induced epitope retrieval was performed using 1mM EDTA in a microwave. Prior to 
staining, the samples were permeabilized with 0.25% Triton X-100 in TBS for 5 min, 
washed twice with TBST and blocked with protein block (Dako) for 30 min. The samples 
were then incubated with the primary antibodies for 1 hr at room temperature, washed thrice 
with TBST and incubated with secondary antibodies for 45 min at room temperature in the 
dark. The coverslips or slides were washed thrice with TBST, once with TBS, mounted 
using Vectashield containing DAPI. Images were captured on a LSM 780 or LSM 880 
confocal microscope (Zeiss) using ZEN 2011 software.
Confocal Live-Cell Time-Lapse Imaging of iFA Disease Model—Cells were 
maintained on the microscope stage in an environmental chamber with controlled 
temperature, CO2 level, and humidity throughout the experiment. Live-cell time-lapse 
imaging was carried out by imaging at 10 × objective mounted on Zeiss LSM-780 inverted 
confocal microscope (Carl Zeiss) at 8-minute intervals for 20 hr.
Detection of Cellular Senescence—iFA cultures were fixed in 1% formaldehyde/0.2% 
glutaraldehyde in PBS for 15 minutes at RT, rinsed in PBS and processed for β-
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galactosidase staining using the senescence detection kit (BioVision) according to the 
manufacturer’s instruction. The cultures were counter-stained with eosin and imaged.
Transmission Electron Microscopy (TEM)—Cells in the iFA model were fixed with 
2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer, pH 7.4 for 30 min at RT, followed 
by overnight incubation at 4°C. Cells were then treated with 0.5% of tannic acid for an hour 
at RT, followed by wash with PBS buffer (5 times) and post fixed in a solution of 1% OsO4 
in PBS, pH 7.2–7.4. The samples were then washed with Na acetate buffer, pH 5.5 (4 times), 
block-stained in 0.5% uranyl acetate for 12 hr at 4°C. The samples were dehydrated in 
graded ethanol 10 minutes each, passed through propylene oxide, and infiltrated in mixtures 
of Epon 812 and propylene oxide 1:1 and then 2:1 for 2 hr each and then infiltrated in pure 
Epon 812 overnight. Upon embedding and curing, sections of 60nm thickness were cut on 
an ultramicrotome (RMC MTX). The sections were deposited carefully on single-hole grids 
coated with Formvar and carbon and double-stained in aqueous solutions of 8% uranyl 
acetate for 25 min at 60°C and lead citrate for 3 minutes at RT. Thin sections subsequently 
were examined with a 100CX JEOL electron microscope.
Immunoblot Analyses—Cells were lysed in RIPA lysis buffer with added protease 
inhibitor cocktail (Roche, USA). Protein concentrations were estimated using qubit 
fluorometer. Samples were prepared by adding an equal volume of 2× SDS sample buffer to 
the samples and denatured by boiling for 5 minutes. Samples were applied and separated 
through Mini-PROTEAN® TGX Stain-Free Precast Gels (Biorad) and transferred to an 
Immobilon PVDF membrane (Millipore, USA). The membranes were blocked with Tris-
buffered saline with 0.05% Tween 20 and 5% skimmed milk for 30 minutes and then treated 
with primary antibodies. The preparative membranes were then incubated with appropriate 
secondary antibodies conjugated to horseradish peroxidase (Invitrogen). The immune-
complexes were visualized with the ECL kit (GE-Healthcare, USA). Bands were quantified 
using Image Lab software/Gel Doc XR+ system, and values were normalized to either total 
protein lanes or actin levels.
RNA Preparation and Expression Analysis—In-vitro cultures of primary fibroblasts 
and cells in the iFA model were washed once with PBS and total RNA from the samples 
were extracted using the RNeasy Mini Kit (QIAGEN) according to the manufacturer’s 
instructions. For the lung slice cultures (LSC), tissues were snap-frozen after treatment and 
stored at −80°C until RNA isolation. Lung slices were homogenized using a handheld 
homogenizer and passing the homogenate through a Qiashredder (QIAGEN). Total RNA 
from the LSC and cells from the disease model were extracted using the RNeasy Mini Kit 
(QIAGEN) according to the manufacturer’s instructions. The RNA concentrations were 
measured on a NanoDrop ND-1000 spectrophotometer. Single-stranded cDNA was 
synthesized from 200ng of total RNA using Superscript IV and random hexamer primers 
(Invitrogen) in a volume of 20 μl. cDNA was then used for qRT-PCR analysis. PCR 
reactions were performed using Taqman Gene Expression Assay mix (Applied Biosystems) 
according to the manufacturer’s instructions. qRT-PCR reactions were performed using the 
StepOnePlus (Applied Biosystems). Relative gene expression was calculated using the 
2−ΔΔCt method, with 18S Cat. # 4331182 (Invitrogen) as housekeeping gene. For the 
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RT2qPCR arrays, cDNA from DMSO and AA5 treated iFA and was added to the RT2 qPCR 
iTaq Universal SYBR green Master Mix (Biorad). 20 μL of the experimental cocktail was 
added to each well of the Fibrosis PCR (QIAGEN). Real-Time PCR was performed on the 
StepOnePlus qPCR system (Applied Biosystems) using SYBR green detection according to 
the manufacturer’s recommendations. All data from the PCR was collected and analyzed by 
SA Bioscience’s PCR Array Data Analysis Web Portal.
Fluorescence-activated cell sorting (FACS)—For determination of various cell 
populations in the iFA model, the cells were dissociated using Accumax (Stem Cell 
Technologies) for 5 minutes, pelleted and resuspended in FACS buffer (3% Fetal Bovine 
Serum /PBS). 1 × 106 cells were incubated with the appropriate conjugated antibody for 20 
minutes at 4°C under shaking conditions. The cells were washed with the FACS buffer and 
acquired using a flow cytometer (BD LSRII) and analyzed using FACS Diva and FlowJo 
softwares.
For dissociation of human lung slice cultures, 48 hours after DMSO or AA5 treatment, the 
samples were dissociated using the Multi Tissue Dissociation Kit (Milteny) (2.35 mL of 
DMEM, 100 μL of Enzyme D, 50 μL of Enzyme R, and 12.5 μL of Enzyme A) using 
gentleMACS Octo Dissociator at 37°C for 40 minutes. The cell suspension was passed 
though 40micron filter and pelleted. Erythrocytes were lysed using the Red Blood Lysis 
Solution (Milteny) for 2 minutes, pelleted and re-suspended in FACS buffer. Total cells were 
stained using the antibodies for 30 minutes followed by washing. The cells were 
resuspended in FACS buffer and analyzed by Flow Cytometry using the FACS Diva (BD 
Biosciences) and FlowJo softwares.
Quantification of Hydroxyproline content in conjunctival and LSCs—
Conjunctiva or LSCs were boiled in 50 μL or 400 μL of 6 M HCl, respectively at 100°C 
overnight. Hydroxyproline levels were measured in the acid hydrolysis method using a kit 
from Biovision Inc. (Milpitas, CA) using the manufacturer’s instructions. The collagen 
content was estimated by either normalizing to total protein content (Conjunctiva) 
(Cedarlane) or by wet weight (LSC)
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical methods relevant to each Figure. are outlined in the Figure legend. Statistical 
analysis was performed using GraphPad Prism software Ver.7 (GraphPad, San Diego, CA, 
USA) by one-way or two-way analysis of variance (ANOVA), with Tukey, Sidak or Dunnett 
tests for post hoc analysis. Sample groups of n = 5 or more, where each replicate (“n”) 
represents entirely separate iFA cultures from different patient lines (biological replicates) or 
lung slice cultures from multiple patients sliced from a different areas of the lung. Different 
areas were used to increase the n value since the extent of fibrosis is heterogeneous even 
within a single patient sample. We anticipated that biologically relevant differences between 
treatment groups would have a large effect size due to heterogeneity expected in patient 
samples. We therefore set our sample size threshold to at least 5 replicates. This ensured our 
samples were large enough to perform analysis of variance. The p value threshold to 
determine significance was set at p = 0.05. Data for quantitative experiments was 
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represented as the mean with error bars representing standard error of the mean. Further 
specifics about the replicates used in each experiment are available in the Figure legends.
DATA AND CODE AVAILABILITY
The accession number for the Fastq files and gene counts for mRNA sequencing of iFA 
model (day4 and day13 and post AA5-prevention and AA5-reversal treatments) and for the 
LSC from IPF patients treated with AA5 or DMSO reported in this paper is GEO: 
GSE98764. Fastq files and gene and exon counts for mRNA sequencing of 8 IPF and 7 
healthy control whole lung tissue samples are available at NCBI’s Sequence Read Archive 
(SRA) and NCBI’s Gene Expression Omnibus (Barrett et al., 2013) through the GEO Series 
accession number GSE52463. The microarray data from kidney samples from healthy 
human subjects and patients with chronic kidney disease is available from GEO: GSE66494. 
The RNA-sequencing data from of liver biopsies from patients presenting with different 
early and late fibrosis stages is available at the European Bioinformatics Institute (EMBL-
EBI) through the accession number ArrayExpress: E-MTAB-6863.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• iPSC-derived cells provide a model for inflammation driven progressive 
fibrosis
• A phenotypic drug screen using the model identified an anti-fibrotic molecule
• The small molecule ameliorates fibrosis in animal and human disease models
• The small molecule targets endogenous agonists of tissue repair
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Figure 1. Generation of the iFA Phenotypic Surrogate of Progressive Fibrosis
(A) Comparative immunofluorescence (IF) images of primary fibroblasts and mesenchymal-
like cell cultures stained for fibroblast (FSP-1) and mesenchymal (VIM) markers cultured on 
13-kPa hydrogels. Phase contrast images show monolayer cultures of the primary fibroblasts 
grown on hydrogels while the mesenchymal-like cells heaped up as scar-like aggregates 
(also called induced fibroblast activation [iFA] cultures) as shown on day 13. Scale bars, 50 
μm.
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(B) Comparative IF images of primary fibroblasts and mesenchymal-like cell cultures on 
days 1, 3, 6, and 9 stained with α-SMA, vimentin (VIM), and EdU after a 6-h EdU 
treatment. Scale bars, 50 μm.
(C) Representative IF images of decellularized primary fibroblast (control) and iFA cultures 
stained for collagen I (top) and α-SMA (bottom). Scale bars, 50 μm.
(D) Single-positive cells for SSEA4, CD105, and CD326 (negative for CD45) were sorted 
from the iFA model and re-cultured on 13-kPa hydrogels (n = 3).
(E) The iFA model created from single-positive cells of CD105, SSEA4, and CD326 in (D) 
were individually reanalyzed using FACS.
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Figure 2. Characterization of the Induced Fibroblast Activation (iFA) Phenotypic Surrogate of 
Progressive Fibrosis
(A) Active TGF-β secreted during the progression of the iFA phenotype (days 2–14) in a 
TGF-β bioassay (n = 3).
(B) Representative immunofluorescent image of iFA model stained for total SMAD3 and p-
SMAD2/3 (S465/S467).
(C) Quantification of cell stiffness of the cells in the iFA model at different time points (days 
1–13) (n = 22).
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(D) Representative image of the iFA model at day 13 of culture stained with p16Ink4 staining 
and counterstained with VIM.
(E and F) Cytokine profiles (E) and HMGB1 (F) levels determined from conditioned media 
of the iFA model at day 13 relative to day 4 (n = 5 in duplicate).
(G) Representative image of the iFA model at day 13 stained for NF-κB p65. HMGB1 was 
translocated from the nucleus to the cytoplasm.
(H) Enrichment analysis of canonical pathways (1,006 MSigDB canonical pathways) in 
transcriptome data of RNA sequencing in day 13 versus day 4 cultures of the iFA model 
compared to the fibrotic organ versus healthy tissue data. Fibrotic organs include IPF versus 
healthy lung (n = 8), advanced (n = 6) versus early (n = 6) liver steatosis, and kidneys from 
chronic kidney disease (n = 46) versus healthy controls (n = 8). Related to Figure S2E and 
Table S1.
Scale bars, 50 mm. Data in figures represent the mean ± SEM; ****p < 0.0001, ***p < 
0.001, **p < 0.01, and *p < 0.05 using two-way ANOVA and Sidak’s multiple comparisons 
test.
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Figure 3. Direct Comparison between the iFA Model and TGF-β-Induced Fibrosis Models 
Commonly Used in Drug Discovery Programs
(A) Heatmap summarizing fold change for 84 fibrosis-related genes exhibiting differential 
expression across the iFA model (day 13 versus day 4) and TGF-β-induced fibrosis models 
(TGF-β-treated versus untreated); SF, skin fibroblasts; LF, normal lung fibroblasts; IPF-LF, 
IPF lung fibroblasts; LX-2, hepatic stellate cell line. Heatmaps show log-base-2-transformed 
data for each experiment mean expression (n = 3) of genes with p value < 0.05 in at least one 
of the samples per gene.
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(B) Densitometric analysis depicting fold change of α-SMA and collagen I in fibrosis 
models (TGF-β-treated versus untreated) and the iFA model (day 13 versus day 4) analyzed 
by immunoblotting normalized to total protein (for α-SMA) or β-actin (for collagen I).
(C) Heatmap summarizing fold change of differential expression of cytokines and growth 
factors in supernatants of fibrosis models (TGF-β-treated versus untreated) and iFA model 
(day 13 versus day 4) (n = 3 in duplicate). Heatmaps show log-base-2-transformed data for 
each experiment mean expression (n = 3 in duplicate) of genes with p value < 0.05 in at least 
one of the samples per protein.
(D) HMGB1 levels determined from conditioned media in the fibrosis models (with and 
without TGF-β treatment) and the iFA model at day 13 relative to day 4 (n = 6).
Data represent the mean ± SEM; ****p < 0.0001 ***p < 0.001, and **p < 0.01 using two-
way ANOVA and Sidak’s multiple comparisons test.
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Figure 4. High-Content Phenotypic Screening Identifies an Anti-fibrotic Small Molecule
(A) Cartoon representing the phenotypic drug screening iFA-prevention assay.
(B) Schematic depicting the screen workflow.
(C) Superimposed representative scatterplot from a single 96-well plate of the iFA-
prevention assay. Green and red dots represent the total number of live cellsand iFA 
phenotypes, respectively, in each well analyzed per the parameters listed in Figure S4A. 
DMSO controls were in wells A1-H1 and A12-H12. The black line is the statistical cutoff of 
the DMSO control used for selecting primary hits (≥80% viability). A hit molecule would be 
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identified as one that has no iFA phenotype (red dot is near/at 0) and cell viability greater 
than 80% (green dot is above the cutoff line).
(D) Prevention of the iFA phenotype in the well containing our “hit” molecule, AA5, 
compared to DMSO control. Scale bar, 750 μm.
(E) Chemical structure of AA5.
(F) Dose response of AA5 showing IC50 of 0.9 μM.
(G) A pre-presentation of the assay performance with Z′ calculation demonstrating a robust 
assay performance using the number of iFA phenotypes.
(H) The assay performance with Z′ calculation demonstrating again a robust assay 
performance using the phenotypic cell index (PI).
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Figure 5. AA5 Induces Acute-Phase Response Proteins Promoting Resolution of Fibrosis
(A) Representative DMSO-treated, AA5-prevention (AA5p), and AA5-resolution (AA5r) 
iFA cultures immunostained for VIM and α-SMA (top panels) and collagen I and α-SMA 
(bottom panels). Scale bar, 50 μm.
(B) Quantification of stiffness of the cells in the DMSO-treated, AA5p, and AA5r iFA 
model.
(C) Secreted levels of HMGB1 in the iFA model during AA5p and AA5r treatments in 
comparison to DMSO-treated controls.
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(D and E) ClueGO clustering analysis results of up- (red) and downregulated (blue) genes in 
a pairwise comparison of AA5p (D) or AA5r (E) treatment with DMSO-treated iFA model. 
p values of ≤ 0.05 are shown.
(F) Cytokine profiles of acute-phase proteins in supernatants of the iFA model at day 13 
relative to day 4 cytokines in AA5r or AA5p versus DMSO-treated cells(n = 4 in duplicate).
(G) Cytokine profiles of proteins secondary to acute-phase response in supernatants from the 
iFA model at day 13 relative to day 4 cytokines in AA5r or AA5pversus DMSO-treated cells 
(n = 4 in duplicate).
(H) Comparison of gene expression fold change levels of PTX3 and NPTX1 and scavenger 
receptor CD163L1 in the AA5r- and AA5p-treated iFA model when compared to the 
DMSO-treated iFA cultures (n = 5).
(I) Time-dependent fold increase in secreted PTX3 and NPTX1 on AA5p and AA5r 
treatment measured in supernatants collected on day 13 (AA5p) and 48 h (AA5r) of 
treatment when compared to DMSO controls in the iFA model (n = 4).
(J) Densitometric analysis depicting fold change of p-SMAD2/3 in the iFA model with 
DMSO, AA5-prevention, and AA5-resolution treatments analyzed by immunoblotting 
normalized to total protein.
Data are presented as the mean ± SEM. ****p < 0.0001, ***p < 0.001, and **p < 0.01 using 
one- or two-way ANOVA and Dunnett or Sidaks’s multiple comparison test.
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Figure 6. Ex Vivo Analyses Confirm the Anti-fibrotic Efficacy of the Hit Molecule in Human 
Fibrotic Samples
(A) Fold change of gene expression in AA5-treated lung slice cultures (LSCs) relative to 
DMSO-treated controls at 48 h (n = 4). Data represent mean ± SEM. ***p < 0.001, **p < 
0.01, and *p < 0.05 using two-way ANOVA and Sidak’s multiple comparison test.
(B) Relative secreted levels of fibrosis-related proteins in supernatants of AA5-treated LSC 
cultures compared to DMSO-treated controls at 48 h (n = 9).
(C) Relative secreted levels of HMGB1 in AA5-treated LSC cultures compared to DMSO-
treated controls at 48 h (n = 9).
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(D) Representative image of DMSO- and AA5-treated LSC stained for HMGB1 counter 
stained for VIM and DAPI. Insets are higher magnification images; scalebar, 50 μm.
(E) Representative FACS plots revealing expression of SSEA4+ population in LSCs treated 
with DMSO or AA5. Inset shows quantitative data of SSEA4+ cells. Data represent mean ± 
SEM. ***p < 0.001 using two-tailed paired t test.
(F) ClueGO clustering analysis results of up- (red) and downregulated (blue) genes in a 
pairwise comparison of AA5- versus DMSO-treated LSCs (p % 0.05).
(G and H) Fold change of expression of PTX3, NPTX1 and CD163L1 in AA5-treated LSCs 
relative to DMSO-treated controls at 48 h at mRNA (G; n = 6) and secreted protein (H; n = 
6) levels.
(I) Representative images from wells of the iFA model treated with the DMSO, 10 μM AA5, 
or 3.75 μg/ml IFN-γ stained with Calcein AM and DAPI (left panel). Scale bars, top panel - 
750 μm, bottom panel - 50 μm.
(J) Relative fold change of secreted proteins in LSCs treated with 3.75 μg/ml rIFN-γ for 48 
h in comparison to DMSO-treated controls (n = 4).
Data represent min-max and median protein abundance; ****p < 0.0001 ***p < 0.001 **p < 
0.01 *p < 0.05 using two-way ANOVA and Sidak’s multiple comparison test.
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Figure 7. In Vivo Analyses Confirm the Anti-fibrotic Efficacy of the Hit Molecule
(A) Schema illustrating the experiment to induce and treat ocular fibrosis in mice in a dose-
dependent manner.
(B) Representative images of eyes of mice from naive, OVA-sensitized and either DMSO- or 
AA5-treated animals on day 21.
(C) Representative Gömöri trichrome stained sections of whole eyes (n = 12 per group). 
Scale bar: 50 μm.
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(D and E) Ocular surface inflammatory score in OVA-treated mice (n = 12) treated daily 
with topical eye drops containing DMSO or (0.1–1,000 μg) AA5 in fibrosis prevention (D) 
and resolution (E) studies.
(F and G) Total collagen content in conjunctival tissue in naive, OVA-, DMSO-, and AA5-
prevention (F) or AA5-resolution (G) treated animals following ocular scarring (n = 12).
(H) Schema illustrating the experiment to induce and treat IPF in mice.
(I) Hydroxyproline content in lung tissue collected on day 21 post -BLM injury with and 
without AA5 (n = 8).
(J) Percentage fibrotic area measured using the spline contour tool in each sectioned lobe. 
Data represent mean of two samples analyzed by unpaired t test(***p < 0.001). Related to 
Figure S7A.
(K) Representative trichrome-stained sections of BLM-treated lungs with and without AA5 
collected at day 21 used for scoring fibrotic area in Figure 7J. Scale bar, 200 μm.
Data represent min-max and median. ****p < 0.0001, ***p < 0.001, **p < 0.01, and *p < 
0.05 using one-way ANOVA and Sidak’s multiple comparison test.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit Vimentin (VIM) Bioss Cat# bs-0756R; 
RRID:AB_10855343
Mouse α-SMA Sigma-Aldrich Cat# A5228; RRID:AB_262054
Rabbit Collagen I R and D systems Cat# AF6220; RRID:AB_10891543
Rabbit OCT4 Cell Signaling Technology Cat# 2750; RRID:AB_823583
Rabbit Keratin (K) 5 Covance Cat # PRB-160P; RRID:AB_291581
Rat SMAD3 R and D systems Cat# MAB4038; 
RRID:AB_2192880
Rabbit p-SMAD2/3 R and D systems Cat# MAB8935; 
RRID:AB_2313773
Goat P16INK4A R and D systems Cat# AF5779; RRID:AB_1964666
Rabbit NF-kB p65 Bioss Cat# bs-0465R; 
RRID:AB_10855447
Mouse HMGB1 Sigma-Aldrich Cat# WH0003146M8; 
RRID:AB_1841963
Rabbit ACTIN Santa Cruz Biotech Cat# sc-7210; RRID:AB_2223518
Rabbit PCNA Abcam Cat# ab92552; RRID:AB_10561973
Mouse CD163L1 Abcam Cat# ab126756; 
RRID:AB_11144517
Mouse NPTX1 Millipore Cat# MAB1592; RRID:AB_94275
Mouse CD14-AlexaFluor®405 R and D systems Cat# FAB3832V; 
RRID:AB_2313773
Mouse CD68-PE eBiosciences Cat# 2–0681–82
Mouse CD32-FITC eBiosciences Cat# 11–0329–42; 
RRID:AB_11150052
Rat CD11b-APC R and D systems Cat# FAB1124A; RRID:AB_356991
Rat CD44–405 R and D systems Cat# FAB6127V; 
RRID:AB_2313773
Mouse CD326-PE Biolegend Cat# 324205; RRID:AB_756079
Mouse CD45-AlexaFluor®488 R and D systems Cat# FAB1430G; 
RRID:AB_2313773
Mouse SSEA4-APC R and D systems Cat# FAB1435A; RRID:AB_494994
Rat CD105-AlexaFluor® 488 Biolegend Cat# 120405; RRID:AB_961056
Donkey Anti-rabbit AlexaFluor®488 Thermofisher scientific Cat# A-21206; RRID:AB_141708
Donkey Anti-rabbit AlexaFluor®594 Thermofisher scientific Cat# A-21207; RRID:AB_141637
Donkey Anti-mouse AlexaFluor®488 Thermofisher scientific Cat# A-21202; RRID:AB_141607
Donkey Anti-mouse AlexaFluor®594 Thermofisher scientific Cat# A-21203; RRID:AB_2535789
Donkey Anti-goat AlexaFluor®488 Thermofisher scientific Cat# A-11055; RRID:AB_2534102
Mouse Fibroblast Surface Protein-1 (FSP1) Abcam Cat# ab11333; RRID: AB_297939
Bacterial and Virus Strains
STEMCCA lentivirus Gift from Dr. Darrell Kotton, Boston 
University, MA
www.kottonlab.com
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REAGENT or RESOURCE SOURCE IDENTIFIER
MGC premier Lentiviral ORF Transomic Technologies TOH7000
Biological Samples
Deidentified human fresh lung tissue specimens Ronald Reagan UCLA Medical Center N/A
Chemicals, Peptides, and Recombinant Proteins
Acrylamide AMRESCO M121
Bis Acrylamide Sigma-Aldrich 161–0142
Sodium bisulfate Sigma-Aldrich 71656
Dimethyldichlorosilane Sigma-Aldrich 440272–100ml
p-benzoquinone Sigma-Aldrich B10358
Dioxane Sigma-Aldrich 296309
rhTGFβ1 Peprotech 100–21-B
Calcein AM Thermo Fisher C1430
Bleomycin Hydrochloride Sigma Aldrich B5507–15UN
Ovalbumin Sigma-Aldrich A5503
Pertussis toxin Sigma Aldrich P7208
Imject Alum Thermo Scientific 77161
Critical Commercial Assays
Bright-Glo Luciferase Assay System Promega E2610
Click-iT EdU Cell Proliferation Kit for Imaging, Alexa 
Fluor 488
Thermo Fisher C10337
Milliplex human cytokine/chemokine Panel IV Millipore HCY4MG-64K-PX21
Human TIMP Panel 2 Millipore HTMP2MAG-54K
Human TGFβ 1,2,3 magnetic bead kits Millipore TGFBMAG-64K-03
Human Cytokine Array / Chemokine Array 64-Plex 
Discovery Assay
Eve Technologies HD65
Human HMGB1 ELISA kit LSBio LS-F11641
Human NPTX1 ELISA kit LSBio LS-F6568
Senescence Detection Kit Biovision K320
Hydroxyproline Assay Kit Biovision K555–100
Deposited Data
iFA_model_stepwise_progression (D4 versus D13) 
transcriptome analysis
This paper GSE98764
iFA_model versus AA5 treatment transcriptome analysis This paper GSE98764
LSC versus AA5 treatment transcriptome analysis This paper GSE98764
Experimental Models: Cell Lines
MLEC-PAI-1-Luc cell reporter cell Gift from Dr. Eric White, University of 
Michigan, Michigan
Mazzieri et al., 2000
LX-2 Human Hepatic Stellate Cell Line Millipore SCC064
Experimental Models: Organisms/Strains
C57BL/6J The Jackson Laboratory 000664
Oligonucleotides
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REAGENT or RESOURCE SOURCE IDENTIFIER
q-PCR Taqman Probes This Paper Table S3
Software and Algorithms
Gene Set Enrichment Analysis (GSEA) http://software.broadinstitute.org/gsea/
index.jsp
Subramanian et al. (2005) and 
Mootha et al. (2003)
The Rank Rank Hypergeometric Overlap (RRHO) 
Analysis
https://systems.crump.ucla.edu/rankrank/
rankranksimple.php
Plaisier et al., 2010
Cytoscape Cytoscape App Store Bindea et al., 2009
Others
Human healthy versus IPF lung transcriptome analysis PMID: 24647608 GSE52463
Human healthy kidney versus chronic kidney disease 
transcriptome analysis
PMID: 26317775 GSE66494
Human early versus advanced liver fibrosis transcriptome 
analysis
PMID: 30046009 E-MTAB-6863
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